| Literature DB >> 27466272 |
Farzad Asadi1, Dorothy Michalski1, Jim Karagiannis2.
Abstract
Fission yeast cells treated with low doses of the actin depolymerizing drug, latrunculin A (LatA), delay entry into mitosis via a mechanism that is dependent on both the Clp1p and Rad24p proteins. During this delay, cells remain in a cytokinesis-competent state that is characterized by continuous repair and/or reestablishment of the actomyosin ring. In this manner, cells ensure the faithful completion of the preceding cytokinesis in response to perturbation of the cell division machinery. To uncover other genes with a role in this response, or simply genes with roles in adapting to LatA-induced stress, we carried out a genome-wide screen and identified a group of 38 gene deletion mutants that are hyper-sensitive to the drug. As expected, we found genes affecting cytokinesis and/or the actin cytoskeleton within this set (ain1, acp2, imp2). We also identified genes with roles in histone modification (tra1, ngg1), intracellular transport (apl5, aps3), and glucose-mediated signaling (git3, git5, git11, pka1, cgs2). Importantly, while the identified gene deletion mutants are prone to cytokinesis failure in the presence of LatA, they are nevertheless fully capable of cell division in the absence of the drug. These results indicate that fission yeast cells make use of a diverse set of regulatory modules to counter abnormal cytoskeletal perturbations, and furthermore, that these modules act redundantly to ensure cell survival and proliferation.Entities:
Keywords: Mutant Screen Report; Schizosaccharomyces pombe; actin; cell division; cytokinesis; latrunculin A
Mesh:
Substances:
Year: 2016 PMID: 27466272 PMCID: PMC5068959 DOI: 10.1534/g3.116.032664
Source DB: PubMed Journal: G3 (Bethesda) ISSN: 2160-1836 Impact factor: 3.154
Figure 1Primary screen. (A) All 3400 gene deletion strains from the Bioneer collection were spotted to YES-agar plates containing DMSO (solvent control) or 0.4 μM LatA and then incubated for 3 d at 30°. Two representative plates from the screen are shown. A wild-type strain, as well as two hyper-sensitive mutants, lsk1Δ and pap1Δ, were used as controls (green circles). Two “hits,” rpl2102 and mcl1Δ, are also highlighted (red circles). (B) Venn diagram analysis of the three trials of the primary screen. Thirty-eight hits were common to all three trials and comprise the high-confidence group (red). Seventy-seven hits were common to two of the trials and comprise the medium-confidence group (green). One hundred and seventy-three hits were common to one of the three trials and comprise the low-confidence group (blue).
Figure 2Spot assays. Ten-fold serial dilution of cultures of the indicated genotypes were spotted onto YES-agar plates containing DMSO (solvent control) or 0.1, 0.2, or 0.3 μM LatA. Photographs were taken after 4 d incubation at 30°.
Figure 3Disk diffusion assays. (A) Filter paper disks soaked with 5 µl of DMSO (solvent control) or 2.2, 4.4, or 6.6 µM LatA, were placed on YES-agar plates impregnated with the indicated gene deletion mutants. Photographs were taken after 4 d incubation at 30°. The zones of growth inhibition surrounding each disk were measured and analyzed as described in Materials and Methods. (B) A plot of the area of the zone of inhibition vs. LatA concentration for a representative group of 10 gene deletion strains exhibiting varying sensitivity to LatA. The linear regression line through the points is plotted. The slope of this line was used as a quantitative measure to rank the LatA sensitivity of each strain.
Ranking of the LatA sensitivity of each gene deletion mutant based on linear regression analysis of data plotting the area of the zone of inhibition (pixels) vs. LatA concentration (µM)
| Gene Deletion | Rank (Most Sensitive to Least Sensitive) | Slope of the Linear Regression Line (pixels/µM) |
|---|---|---|
| 1 | 26,505 | |
| 2 | 22,989 | |
| 3 | 19,765 | |
| 4 | 19,447 | |
| 5 | 19,283 | |
| 6 | 17,437 | |
| 7 | 17,303 | |
| 8 | 17,085 | |
| 9 | 16,543 | |
| SPCC794.03 | 10 | 16,403 |
| SPCC70.06 | 11 | 16,360 |
| SPAC9.02c | 12 | 15,836 |
| 13 | 15,748 | |
| 14 | 15,388 | |
| 15 | 15,216 | |
| SPAC3C7.07c | 16 | 14,287 |
| 17 | 13,785 | |
| SPCC297.05 | 18 | 12,995 |
| 19 | 12,108 | |
| 20 | 10,286 | |
| 21 | 9763 | |
| SPCC4F11.03c | 22 | 9749 |
| 23 | 9289 | |
| 24 | 8890 | |
| 25 | 8717 | |
| 26 | 8480 | |
| 27 | 8312 | |
| 28 | 8062 | |
| 29 | 7802 | |
| SPBC725.10 | 30 | 7485 |
| SPCC1020.07 | 31 | 7064 |
| 32 | 6670 | |
| 33 | 6669 | |
| 34 | 6424 | |
| 35 | 5886 | |
| SPAC3H8.08c | 36 | 5555 |
| 37 | 4862 | |
| 38 | 4711 | |
| 39 | 4080 | |
| Wild type | 40 | 1852 |
Minimum inhibitory concentration of LatA for the indicated gene deletion mutants
| Gene Deletion Mutant | Minimum Inhibitory Concentration (µM) |
|---|---|
| 0.1–0.2 | |
| 0.2 | |
| 0.075 | |
| 0.025–0.075 | |
| SPAC3H8.08c | 0.2 |
| 0.05 | |
| 0.1–0.2 | |
| 0.025 | |
| 0.1–0.2 | |
| 0.2 | |
| >0.2 | |
| 0.1–0.2 | |
| SPAC9.02c | 0.075–0.1 |
| 0.2 | |
| 0.025 | |
| 0.025 | |
| 0.05 | |
| 0.2 | |
| 0.2 | |
| 0.2 | |
| 0.025 | |
| 0.05 | |
| SPCC1020.07 | 0.2 |
| 0.1–0.2 | |
| SPCC4F11.03c | 0.1 |
| 0.075–0.1 | |
| SPCC70.06 | 0.075 |
| 0.05–0.075 | |
| 0.075–0.1 | |
| SPAC3C7.07c | 0.075–0.1 |
| 0.05–0.075 | |
| 0.2 | |
| >0.2 | |
| SPBC725.10 | 0.1–0.2 |
| 0.2 | |
| 0.075 | |
| SPCC297.05 | >0.2 |
| SPCC794.03 | 0.05 |
| 0.05–0.075 | |
| Wild type | >0.2 |
Figure 4The gene deletion mutants of the high-confidence list are prone to cytokinesis failure in the presence of LatA. Cells of the indicated genotype were grown to midlog phase and then treated with DMSO (solvent control) or 0.3 μM LatA for 5 hr. Cells were fixed and stained with DAPI/aniline blue to visualize nuclei and cell/wall septal material, respectively. Four strains from the high-confidence list are shown as representative examples.
Mean percentage of cells (± SD) displaying the indicated phenotype after 5 hr treatment with 0.3 µM LatA (n = 3)
| Gene Deletion Mutant | Uninucleate | Binucleate (Complete Septum) | Binucleate (Fragmented Septum) | Tetranucleate (Fragmented Septum) | Ratio (Fragmented/Nonfragmented) |
|---|---|---|---|---|---|
| 69 ± 14 | 3 ± 3 | 28 ± 15 | 0 | 0.39 | |
| 44 ± 29 | 1 ± 1 | 52 ± 27 | 4 ± 6 | 1.16 | |
| 21 ± 12 | 2 ± 2 | 76 ± 11 | 1 ± 2 | 3.30 | |
| 53 ± 36 | 2 ± 3 | 43 ± 37 | 1 ± 1 | 0.78 | |
| SPAC3H8.08c | 68 ± 18 | 5 ± 7 | 27 ± 11 | 0 | 0.36 |
| 19 ± 14 | 7 ± 6 | 70 ± 9 | 4 ± 3 | 2.66 | |
| 23 ± 5 | 0 | 72 ± 4 | 4 ± 1 | 3.10 | |
| 43 ± 31 | 3 ±5 | 54 ± 35 | 1 ± 1 | 1.18 | |
| 66 ± 20 | 1 ± 1 | 33 ± 20 | 0 | 0.50 | |
| 60 ± 19 | 1 ± 1 | 34 ± 14 | 1 ± 2 | 0.56 | |
| 41 ± 31 | 2 ± 2 | 56 ± 31 | 0 | 1.30 | |
| 51± 18 | 3 ± 6 | 43 ± 14 | 2 ± 3 | 0.79 | |
| SPAC9.02c | 46 ± 27 | 5 ± 6 | 47 ± 34 | 0 | 0.92 |
| 62 ± 14 | 3 ± 4 | 32 ± 9 | 2 ± 3 | 0.48 | |
| 10 ± 5 | 0 | 69 ± 2 | 21 ± 5 | 7.14 | |
| 24 ± 20 | 1 ± 2 | 72 ± 19 | 3 ± 3 | 2.83 | |
| 65 ± 11 | 7 ± 3 | 28 ± 7 | 0 | 0.39 | |
| 54 ± 19 | 1 ± 2 | 44 ± 21 | 0 | 0.81 | |
| 22 ± 4 | 2 ± 3 | 75 ± 6 | 1 ± 1 | 3.14 | |
| 63 ± 9 | 2 ± 3 | 34 ± 6 | 0 | 0.52 | |
| 18 ± 5 | 11 ± 9 | 63 ± 14 | 8 ± 2 | 2.16 | |
| 47 ± 12 | 8 ± 7 | 43 ± 12 | 2 ± 2 | 0.79 | |
| SPCC1020.07 | 47 ± 32 | 3 ± 1 | 49 ± 30 | 1 ± 1 | 0.99 |
| 53 ± 21 | 0 ± 0 | 45 ± 21 | 2 ± 2 | 0.84 | |
| SPCC4F11.03c | 31 ± 14 | 6 ± 9 | 58 ± 21 | 5 ± 2 | 1.54 |
| 39 ± 12 | 5 ± 6 | 55 ± 17 | 1 ± 1 | 1.26 | |
| SPCC70.06 | 41 ± 20 | 5 ± 5 | 52 ± 26 | 2 ± 2 | 1.12 |
| 32 ± 17 | 2 ± 2 | 66 ± 18 | 0 | 1.91 | |
| 39 ± 27 | 3 ± 3 | 58 ± 29 | 1 ± 1 | 1.38 | |
| SPAC3C7.07c | 54 ± 10 | 9 ± 2 | 35 ± 12 | 2 ± 3 | 0.56 |
| 70 ± 8 | 8 ± 8 | 22 ± 5 | 0 | 0.28 | |
| 55 ± 16 | 2 ± 2 | 42 ± 19 | 2 ± 3 | 0.74 | |
| 48 ± 5 | 3 ± 1 | 48 ± 3 | 1 ± 1 | 0.94 | |
| SPBC725.10 | 53 ± 24 | 1 ± 2 | 45 ± 23 | 0 | 0.82 |
| 58 ± 8 | 5 ± 5 | 37 ± 3 | 0 | 0.60 | |
| 60 ± 4 | 4 ± 4 | 36 ± 6 | 0 | 0.56 | |
| SPCC297.05 | 59 ± 27 | 2± 3 | 38 ± 28 | 0 | 0.63 |
| SPCC794.03 | 60 ± 16 | 7± 6 | 31± 14 | 1 ± 2 | 0.47 |
| 46 ± 11 | 1 ± 1 | 53 ± 11 | 0 | 1.14 | |
| Wild type | 88 ± 3 | 12 ± 3 | 2 ± 1 | 0 | 0.02 |
Gene Ontology (GO) term enrichments identified by BiNGO using the primary screen gene list as input
| Category Name | GO ID | Gene Set Name | Corrected p-Value | Genes |
|---|---|---|---|---|
| Cellular Component | GO:0000124 | SAGA Complex | 6.67 × 10−5 | |
| Cellular Component | GO:0016272 | Prefoldin Complex | 9.60 × 10−4 | |
| Cellular Component | GO:0034967 | Set3 Complex | 1.64 × 10−3 | |
| Cellular Component | GO:0030123 | AP-3 Adaptor Complex | 1.64 × 10−3 | |
| Biological Process | GO:0016570 | Negative Regulation of Transcription by Glucose | 3.01 × 10−6 | |
| Biological Process | GO:0045761 | Regulation of Adenylate Cyclase Activity | 1.64 × 10−3 | |
| Biological Process | GO:006338 | Chromatin Remodeling | 4.17 × 10−3 | |
| Biological Process | GO:007021 | Tubulin Complex Assembly | 2.22 × 10−3 | |
| Molecular Function | GO:0003712 | Transcription Cofactor Activity | 1.81 × 10−3 |
Figure 5BiNGO GO term enrichment analysis visualized with Cytoscape using a hierarchical layout. The 288 hits of the primary screen were used as input against a background of the 3400 S. pombe genes of the Bioneer deletion set. Significant enrichments (p < 0.005) are highlighted in yellow. (A) GO Cellular Component. (B) GO Molecular Function. (C) GO Biological Process.